Download PDF
Semin Respir Crit Care Med 2005; 26(2): 221-234
DOI: 10.1055/s-2005-869541
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Role of Bronchodilators in Chronic Obstructive Pulmonary Disease

Max M. Weder1 , James F. Donohue1
  • 1Division of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Further Information

Publication History

Publication Date:
27 April 2005 (online)

    Permissions and Reprints

ABSTRACT

The prevalence of chronic obstructive pulmonary disease (COPD) continues to be on the rise. Bronchodilators are first line agents for the symptomatic management of this disease and have proven to be effective in both stable disease status and exacerbations. The stepwise escalation of therapy for COPD according to severity has been outlined in international guidelines. Different classes of bronchodilators exist. The most experience is available for short-acting β-agonists and anticholinergics. These agents are mainly recommended for the treatment of mild COPD and for symptomatic patients on an as needed basis. Long-acting β-agonists and anticholinergics have been developed more recently. They are more convenient to use for patients with advanced disease who require maintenance therapy with bronchodilators, and have been shown in this group of patients to provide superior efficacy compared with short-acting agents. Tiotropium, a long-acting anticholinergic, appears to be particularly powerful and may eventually replace ipratropium as the primary agent for COPD treatment. In contrast, the usage of theophylline, which used to be part of the mainstay of treatment for COPD, has declined, mainly secondary to a narrow therapeutic margin and side effects, but it is inexpensive and still has its role. New agents like phosphodiesterase-4-inhibitors are interesting substances that may become important adjuncts in COPD management, but there is limited experience so far. None of the bronchodilators have been shown to change outcome in COPD, but this issue is under active investigation.

KEYWORDS

COPD - bronchodilators - therapy guidelines

REFERENCES

  • 1 Pauwels R A, Buist A S, Calverley P M, Jenkins C R, Hurd S S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.  Am J Respir Crit Care Med. 2001;  163 1256-1276
    CrossrefPubMedGoogle Scholar
  • 2 Hogg J C, Chu F, Utokaparch S et al.. The nature of small-airway obstruction in chronic obstructive pulmonary disease.  N Engl J Med. 2004;  350 2645-2653
    CrossrefPubMedGoogle Scholar
  • 3 Celli B R, Cote C G, Marin J M et al.. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.  N Engl J Med. 2004;  350 1005-1012
    CrossrefPubMedGoogle Scholar
  • 4 Anthonisen N R, Connett J E, Kiley J P et al.. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.  JAMA. 1994;  272 1497-1505
    CrossrefPubMedGoogle Scholar
  • 5 Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol.  Eur Respir J. 2004;  24 206-210
    CrossrefPubMedGoogle Scholar
  • 6 Calverley P M, Burge P S, Spencer S, Anderson J A, Jones P W. Bronchodilator reversibility testing in chronic obstructive pulmonary disease.  Thorax. 2003;  58 659-664
    CrossrefPubMedGoogle Scholar
  • 7 Dorinsky P M, Reisner C, Ferguson G T, Menjoge S S, Serby C W, Witek Jr T J. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD.  Chest. 1999;  115 966-971
    CrossrefPubMedGoogle Scholar
  • 8 Donohue J F, Anderson W, Wiesniewski M et al.. Demographics and bronchoreversibility of salmeterol and ipratropium in a large population of patients with mild-to-moderate COPD [abstract].  Am J Respir Crit Care Med. 1997;  155 A227
    PubMedGoogle Scholar
  • 9 Mahler D A, Wire P, Horstman D et al.. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2002;  166 1084-1091
    CrossrefPubMedGoogle Scholar
  • 10 Anthonisen N R, Wright E C. Bronchodilator response in chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1986;  133 814-819
    PubMedGoogle Scholar
  • 11 Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses.  Chest. 2003;  123 1441-1449
    CrossrefPubMedGoogle Scholar
  • 12 Di Marco F, Milic-Emili J, Boveri B et al.. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD.  Eur Respir J. 2003;  21 86-94
    PubMedGoogle Scholar
  • 13 Newton M F, O'Donnell D E, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation.  Chest. 2002;  121 1042-1050
    CrossrefPubMedGoogle Scholar
  • 14 Goodman D E, Israel E, Rosenberg M, Johnston R, Weiss S T, Drazen J M. The influence of age, diagnosis, and gender on proper use of metered-dose inhalers.  Am J Respir Crit Care Med. 1994;  150(5 Pt 1) 1256-1261
    CrossrefPubMedGoogle Scholar
  • 15 Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol.  Respir Care. 2002;  47 1406-1416 , discussion 1416-1418
    PubMedGoogle Scholar
  • 16 Green S A, Spasoff A P, Coleman R A, Johnson M, Liggett S B. Sustained activation of a G protein-coupled receptor via “anchored” agonist binding: molecular localization of the salmeterol exosite within the 2-adrenergic receptor.  J Biol Chem. 1996;  271 24029-24035
    CrossrefPubMedGoogle Scholar
  • 17 Barnes P J. Beta-adrenergic receptors and their regulation.  Am J Respir Crit Care Med. 1995;  152 838-860
    CrossrefPubMedGoogle Scholar
  • 18 Ram F S, Sestini P. Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis.  Thorax. 2003;  58 580-584
    CrossrefPubMedGoogle Scholar
  • 19 Sin D D, McAlister F A, Man S F, Anthonisen N R. Contemporary management of chronic obstructive pulmonary disease: scientific review.  JAMA. 2003;  290 2301-2312
    CrossrefPubMedGoogle Scholar
  • 20 Sears M R. Adverse effects of beta-agonists.  J Allergy Clin Immunol. 2002;  110(suppl 6) S322-S328
    CrossrefPubMedGoogle Scholar
  • 21 Schultze-Werninghaus G. Multicenter 1-year trial on formoterol, a new long-acting beta 2-agonist, in chronic obstructive airway disease.  Lung. 1990;  168(suppl): 83-89
    PubMedGoogle Scholar
  • 22 Appleton S, Poole P, Smith B, Veale A, Bara A. Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation.  Cochrane Database Syst Rev. 2002;  3CD002986
    PubMedGoogle Scholar
  • 23 Jones P W, Bosh T K. Quality of life changes in COPD patients treated with salmeterol.  Am J Respir Crit Care Med. 1997;  155 1283-1289
    PubMedGoogle Scholar
  • 24 Taccola M, Bancalari L, Ghignoni G, Paggiaro P L. Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease.  Monaldi Arch Chest Dis. 1999;  54 302-306
    PubMedGoogle Scholar
  • 25 Celik G, Kayacan O, Beder S, Durmaz G. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action.  Respiration. 1999;  66 434-439
    CrossrefPubMedGoogle Scholar
  • 26 Ferguson G T, Funck-Brentano C, Fischer T, Darken P, Reisner C. Cardiovascular safety of salmeterol in COPD.  Chest. 2003;  123 1817-1824
    CrossrefPubMedGoogle Scholar
  • 27 Donohue J F, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD.  Respir Med. 2003;  97 1014-1020
    CrossrefPubMedGoogle Scholar
  • 28 Nelson H S, Bensch G, Pleskow W W et al.. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma.  J Allergy Clin Immunol. 1998;  102(6 Pt 1) 943-952
    PubMedGoogle Scholar
  • 29 Gawchik S M, Saccar C L, Noonan M, Reasner D S, DeGraw S S. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients.  J Allergy Clin Immunol. 1999;  103 615-621
    PubMedGoogle Scholar
  • 30 Nowak R M, Emerman C L, Schaefer K, Disantostefano R L, Vaickus L, Roach J M. Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study.  Am J Emerg Med. 2004;  22 29-36
    CrossrefPubMedGoogle Scholar
  • 31 Carl J C, Myers T R, Kirchner H L, Kercsmar C M. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma.  J Pediatr. 2003;  143 731-736
    CrossrefPubMedGoogle Scholar
  • 32 Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma.  Chest. 2003;  123 128-135
    CrossrefPubMedGoogle Scholar
  • 33 Salathe M. Effects of beta-agonists on airway epithelial cells.  J Allergy Clin Immunol. 2002;  110(suppl 6) S27 5-S281
    PubMedGoogle Scholar
  • 34 Farmer P, Pugin J. Beta-adrenergic agonists exert their “anti-inflammatory” effects in monocytic cells through the IkappaB/NF-kappaB pathway.  Am J Physiol Lung Cell Mol Physiol. 2000;  279 L675-L682
    PubMedGoogle Scholar
  • 35 Factor P, Adir Y, Mutlu G M, Burhop J, Dumasius V. Effects of beta2-adrenergic receptor overexpression on alveolar epithelial active transport.  J Allergy Clin Immunol. 2002;  110(suppl 6) S242-S246
    CrossrefPubMedGoogle Scholar
  • 36 Philipson L H. Beta-agonists and metabolism.  J Allergy Clin Immunol. 2002;  110(6 Suppl) S313-S317
    CrossrefPubMedGoogle Scholar
  • 37 Adcock I M, Maneechotesuwan K, Usmani O. Molecular interactions between glucocorticoids and long-acting beta2-agonists.  J Allergy Clin Immunol. 2002;  110(suppl 6) S261-S268
    CrossrefPubMedGoogle Scholar
  • 38 Hanania N A, Darken P, Horstman D et al.. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.  Chest. 2003;  124 834-843
    CrossrefPubMedGoogle Scholar
  • 39 Calverley P, Pauwels R, Vestbo J et al.. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.  Lancet. 2003;  361 449-456
    CrossrefPubMedGoogle Scholar
  • 40 Nannini L, Cates C J, Lasserson T J, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler for chronic obstructive pulmonary disease.  Cochrane Database Syst Rev. 2004;  3CD003794
    PubMedGoogle Scholar
  • 41 Donohue J F, Kalberg C, Emmett A, Merchant K, Knobil K. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.  Treat Respir Med. 2004;  3 173-181
    PubMedGoogle Scholar
  • 42 Szafranski W, Cukier A, Ramirez A et al.. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.  Eur Respir J. 2003;  21 74-81
    CrossrefPubMedGoogle Scholar
  • 43 Calverley P M, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease.  Eur Respir J. 2003;  22 912-919
    CrossrefPubMedGoogle Scholar
  • 44 van Noord J A, Bantje T A, Eland M E, Korducki L, Cornelissen P J. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group.  Thorax. 2000;  55 289-294
    CrossrefPubMedGoogle Scholar
  • 45 Casaburi R, Briggs Jr D D, Donohue J F, Serby C W, Menjoge S S, Witek Jr T J. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group.  Chest. 2000;  118 1294-1302
    CrossrefPubMedGoogle Scholar
  • 46 Casaburi R, Mahler D A, Jones P W et al.. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.  Eur Respir J. 2002;  19 217-224
    CrossrefPubMedGoogle Scholar
  • 47 Gross N J, Petty T L, Friedman M, Skorodin M S, Silvers G W, Donohue J F. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease: a three-center study.  Am Rev Respir Dis. 1989;  139 1188-1191
    PubMedGoogle Scholar
  • 48 Dahl R, Greefhorst L A, Nowak D et al.. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2001;  164 778-784
    PubMedGoogle Scholar
  • 49 Matera M G, Cazzola M, Vinciguerra A et al.. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease.  Pulm Pharmacol. 1995;  8 267-271
    PubMedGoogle Scholar
  • 50 van Noord J A, Smeets J J, Custers F L, Korducki L, Cornelissen P J. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease.  Eur Respir J. 2002;  19 639-644
    CrossrefPubMedGoogle Scholar
  • 51 Donohue J F, van Noord J A, Bateman E D et al.. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol.  Chest. 2002;  122 47-55
    CrossrefPubMedGoogle Scholar
  • 52 Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.  Thorax. 2003;  58 399-404
    CrossrefPubMedGoogle Scholar
  • 53 McNicholas W T, Calverley P M, Lee A, Edwards J C. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD.  Eur Respir J. 2004;  23 825-831
    CrossrefPubMedGoogle Scholar
  • 54 Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes.  Chest. 2003;  124 1743-1748
    CrossrefPubMedGoogle Scholar
  • 55 O'Donnell D E, Fluge T, Gerken F et al.. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.  Eur Respir J. 2004;  23 832-840
    PubMedGoogle Scholar
  • 56 Van Andel A E, Reisner C, Menjoge S S, Witek T J. Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995.  Chest. 1999;  115 703-707
    CrossrefPubMedGoogle Scholar
  • 57 Rossi A, Kristufek P, Levine B E et al.. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.  Chest. 2002;  121 1058-1069
    CrossrefPubMedGoogle Scholar
  • 58 Cazzola M, Di Lorenzo G, Di Perna F, Calderaro F, Testi R, Centanni S. Additive effects of salmeterol and fluticasone or theophylline in COPD.  Chest. 2000;  118 1576-1581
    CrossrefPubMedGoogle Scholar
  • 59 ZuWallack R L, Mahler D A, Reilly D et al.. Salmeterol plus theophylline combination therapy in the treatment of COPD.  Chest. 2001;  119 1661-1670
    CrossrefPubMedGoogle Scholar
  • 60 Sturton G, Fitzgerald M. Phosphodiesterase 4 inhibitors for the treatment of COPD.  Chest. 2002;  121(5 Suppl) 192S-196S
    CrossrefPubMedGoogle Scholar
  • 61 Compton C H, Gubb J, Nieman R et al.. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study.  Lancet. 2001;  358 265-270
    CrossrefPubMedGoogle Scholar
  • 62 Bredenbröker D S J, Leichtl S, Rathgeb F, Wurst W. Roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease [abstract].  Eur Respir J. 2002;  20(Suppl 38) 374S
    PubMedGoogle Scholar
  • 63 Agnew J E, Little F, Pavia D, Clarke S W. Mucus clearance from the airways in chronic bronchitis: smokers and ex-smokers.  Bull Eur Physiopathol Respir. 1982;  18 473-484
    PubMedGoogle Scholar
  • 64 Bennett W D, Chapman W F, Mascarella J M. The acute effect of ipratropium bromide bronchodilator therapy on cough clearance in COPD.  Chest. 1993;  103 488-495
    PubMedGoogle Scholar
  • 65 Bennett W D. Effect of beta-adrenergic agonists on mucociliary clearance.  J Allergy Clin Immunol. 2002;  110(6 Suppl) S291-S297
    CrossrefPubMedGoogle Scholar
  • 66 Frohock J I, Wijkstrom-Frei C, Salathe M. Effects of albuterol enantiomers on ciliary beat frequency in ovine tracheal epithelial cells.  J Appl Physiol. 2002;  92 2396-2402
    PubMedGoogle Scholar

James F DonohueM.D. 

Division of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill

130 Mason Farm Rd., CB# 7020, 4125 Bioinformatics Bldg.

Chapel Hill, NC 27599-7020

Email: james_donohue@med.unc.edu

      >